Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13592556 | 0.82 | HSD17B1 (0.33) | HSD17B1HSD17B2GAARAB9ACDC7 | |
| SCHEMBL13479457 | 0.82 | ALDH1A1 (0.39) | HSD17B1HSD17B2POLBGAACDC7 | |
| SCHEMBL1760856 | 0.79 | GPR35 (0.46) | F10HSD17B10GSK3BTPMTPOLB | |
| SCHEMBL1529419 | 0.78 | PTPN1 (0.44) | F10HSD17B10POLBTSHRPTPN1 | |
| SCHEMBL8306941 | 0.78 | F10 (0.41) | F10HSD17B10GSK3BTPMTPOLB | |
| Hydrochloric Acid SCHEMBL8306944 | 0.78 | GPR35 (0.44) | F10HSD17B10GSK3BTPMTPOLB | |
| SCHEMBL12261073 | 0.76 | GPR35 (0.42) | GSK3BPOLBGAANPC1RAB9A | |
| SCHEMBL14511473 | 0.75 | F10 (0.45) | F10HSD17B10GSK3BTPMTPOLB | |
| SCHEMBL12310911 | 0.74 | MAPT (0.36) | F10HSD17B10POLBGAANPC1 | |
| SCHEMBL12086920 | 0.72 | MAPT (0.47) | HSD17B10GSK3BPOLBGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697354-B1 | ISOTHIAZOLE DIOXIDES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7947720-B2 | 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1434775-A1 | 3,4-DI-SUBSTITUTED MALEIMIDE COMPOUNDS AS CXC-CHEMOKINE RECEPTOR ANTAGONISTS | Schering Corporation (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040106794-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040097547-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | PHARMACOPEIA DRUG DISCOVERY | 2004-05-20 | — | — | US | disclosed |
| WO-2004033440-A1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040034229-A1 | 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-02-19 | — | — | US | disclosed |
| EP-1381590-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | Schering Corporation (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | PHARMACOPEIA, INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2003031440-A1 | 3,4-DI-SUBSTITUTED MALEIMIDE COMPOUNDS AS CXC-CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002083624-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | F10 2328/4885HSD17B10 644/4885GSK3B 3840/4885 |
| US-20040034229-A1 | 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists | CXCR1, CCR1, CCL2 | F10 1792/4885HSD17B10 2254/4885GSK3B 4211/4885 |
| US-20040097547-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, CXCR1, ACKR3 | F10 2424/4885HSD17B10 600/4885GSK3B 3884/4885 |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | CCR1, ACKR3, CXCR1 | F10 3002/4885HSD17B10 788/4885GSK3B 3720/4885 |
| US-20040106794-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, CXCR1, ACKR3 | F10 2424/4885HSD17B10 600/4885GSK3B 3884/4885 |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | CCR1, CXCR1, ACKR3 | F10 2332/4885HSD17B10 895/4885GSK3B 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.